Hot Life Sciences Companies For 2014

Ford Motor Company (F) announced on Wednesday the addition of two new board members.

The automaker named James P. Hackett and John C. Lechleiter as the newest members of the company’s board of directors. Hackett’s new role will begin immediately, while Lechlieter will officially join on October 1, 2013.

Hackett is currently the CEO of Steelcase, Inc–a furniture maker–and also serves on the board of Fifth Third Bancorp, the National Center for Arts and Technology, and the��Gerald R. Ford School of Public Policy and Life Sciences Institute at University of Michigan. Lechlieter is the President and CEO of Eli Lilly and Company, one of the largest pharmaceutical firms in the world, and also serves on the board of Nike, Inc, United Way�Worldwide, Xavier University, the Central Indiana Corporate Partnership and the Life Sciences Foundation.

Top 5 Oil Companies To Own In Right Now: PulteGroup Inc. (PHA)

PulteGroup, Inc., through its subsidiaries, engages in homebuilding and financial services businesses primarily in the United States. The company�s homebuilding business includes the acquisition and development of land primarily for residential purposes within the United States; and the construction of housing on such lands. It offers various home designs, including single-family detached, townhouses, condominiums, and duplexes under the Pulte Homes, Del Webb, and Centex brand names. As of December 31, 2011, its homebuilding operations offered homes for sale in approximately 700 communities. The company�s financial services business consists of mortgage banking and title operations. It arranges financing through the origination of mortgage loans for its homebuyers; sells such loans and related servicing rights; and provides title insurance policies as an agent, and examination and closing services to its home buyers. The company was formerly known as Pulte Homes, Inc. an d changed its name to PulteGroup, Inc. in March 2010. PulteGroup, Inc. was founded in 1956 and is headquartered in Bloomfield Hills, Michigan.

Advisors' Opinion:

• [By DailyFinance Staff]

  LM Otero, AP The housing market has been leading the economic recovery, but have housing stocks hit the ceiling? They're jumping today after a very bullish report on housing starts: New construction projects last month topped the 1 million annual rate for the time since before the financial crisis began in 2008. That's lifted shares of leading homebuilders by two to four percent today, adding to the huge gains over the past year. KB Homes (KBH), Pulte (PHA) and Hovnanian (HOV) have all doubled in price over the past year. Lennar (LEN) is up 44 percent, D.R. Horton (DHI) is up 47 percent and Toll Brothers (TOL) 33 percent. Those gains have prompted several other builders to go public this year. Taylor Morrison Home (TMHC), Tri Pointe, and William Lyon Home have all moved higher since their IPOs. And even though there's plenty of optimism that housing will continue to lead the broader economic recovery, there's some concern that these stocks may slow down. Homebuilder stocks can no longer be considered cheap. So some analysts see alternate routes for investors looking to play the housing boom. One way is through home-improvement retailers, which benefit from sales of both new and existing homes. Other plays include lumber, furniture and appliance companies. It's also worth noting that today's report on home construction showed that starts of single-family homes actually declined in March. It was the more volatile multi-family sector that led the advance. But there may be some stock market opportunities in REITs – real estate investment trusts – which focus on apartments. Among the biggest ones are Post Properties, Essex Property Trust and Associated Estates. They make money from collecting monthly rents. And these stocks generally trade below the value of the properties they own. Even some builders known for single-family homes are moving into the multi-family segment. Lennar announced in January that it plans to enter the apartment rental mar

Hot Life Sciences Companies For 2014: BRE Properties Inc (BRE)

BRE Properties, Inc. (BRE), incorporated in 1970, is a self-administered equity real estate investment trust (REIT) focused on the development, acquisition and management of multifamily apartment communities primarily located in the metropolitan markets within the State of California, and the Seattle, Washington region. BRE also owns and operates communities in the Phoenix, Arizona and in the Denver, Colorado metropolitan markets. As of December 31, 2011, its multifamily portfolio had real estate assets, which included 76 wholly or majority owned stabilized multifamily communities, aggregating 21,336 units in California, Washington and Arizona; 11 stabilized multifamily communities owned through joint ventures comprised of 3,592 apartment units; and seven apartment communities in various stages of construction and development. In October 2013, the Company acquired Jefferson at Hollywood.

During the year ended December 31, 2011, BRE acquired three communities totaling 652 units: Lafayette Highlands, with 150 units, located in Lafayette, California; The Landing at Jack London Square, with 282 units, located in Oakland, California, and The Vistas of West Hills, with 220 units, located in Valencia, California. In addition to the communities, the Company acquired two parcels of land for future development in San Francisco, California�� Mission Bay district, and it purchased a 4.4 acre site contiguous to its existing Park Viridian operating community and its existing second phase land site in Anaheim, California. As of December 31, 2011, BRE had seven sites under development or construction.

During 2011, the Company sold two communities totaling 634 units: Galleria at Towngate, with 268 units located in Moreno Valley, California; and Windrush Village, a 366 unit property located in Colton, California. The two properties sold were located in the eastern half of the Inland Empire. In addition, during 2011, two joint venture assets were sold; The Landing at Bear Creek, a 224 unit j! oint venture community, located in Lakewood, Colorado; and The Pinnacle at Hunters Glen, a 264 unit joint venture community located in Thornton, Colorado.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  BRE Properties (NYSE: BRE) was also up, gaining 11.79 percent to $59.66 after Bloomberg reported that the company is working with Wells Fargo on a possible sale.

Hot Life Sciences Companies For 2014: W.P. Carey & Co. LLC(WPC)

W. P. Carey & Co. LLC, together with its subsidiaries, provides long-term sale-leaseback and build-to-suit transactions for companies worldwide and manages a global investment portfolio. It invests primarily in commercial properties that are each triple-net leased to single corporate tenants, which requires each tenant to pay substantially all of the costs associated with operating and maintaining the property. The company also operates as an advisor to publicly owned, non-actively traded real estate investment trusts, which are sponsored by it under the Corporate Property Associates brand name, as well as invests in similar properties. As of March 31, 2010, its portfolio comprised full or partial ownership interest in 167 properties that totaled approximately 14 million square feet. W. P. Carey & Co. LLC was founded in 1973 and is based in New York, New York.

Advisors' Opinion:

• [By Brad Thomas]

  Finally, here's the report card. Agree has racked up a year-over-year total return of 43.19%. That's not bad, especially when you consider the noise generated by the big boys: Realty Income (O) 32.66%; National Retail Properties (NNN) 47.44%; W.P. Carey (WPC) 57.84%; Spirit Realty (SRC) 35.44%; and American Realty Capital Properties 52.18%.

• [By David Dittman]

  Answer: Realty Income Corp (NYSE: O) and WP Carey & Co (NYSE: WPC), up to 45 and 55, respectively.

  Question: Bell Alliant Inc (TSX: BA, OTC: BLIAF) has been weak/flat even though the overall market has been strong. Great dividend; is it solid? Is it worth continuing to hold?

• [By Dividends4Life]

  W. P. Carey Inc. (WPC) is an independent equity real estate investment trust. The firm also provides long-term sale-leaseback and build-to-suit financing for companies. September 19th the company increased its quarterly dividend 2.4% to $0.86 per share. The dividend is payable October 15, 2013 to stockholders of record as of September 30, 2013. The yield based on the new payout is 5.2%.

• [By Marc Bastow]

  Build-to-suite properties real estate investment trust (REIT) W.P. Carey (WPC) raised its quarterly dividend 1.2% to 87 cents per share, payable on Jan. 15 to shareholders of record as of Dec. 31. This marks the 51st consecutive annual dividend increase for WPC.
  WPC Dividend Yield: 5.67%

Hot Life Sciences Companies For 2014: AVEO Pharmaceuticals Inc.(AVEO)

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of cancer therapeutics. The company?s lead product candidate, Tivozanib (AV-951), is a novel, highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2, and 3. It is also leading the clinical development of AV-299, which includes conducting multiple Phase I clinical trials and preparing for the conduct of multiple Phase II clinical trials. The company?s product candidate in preclinical development is AV-203, a potent ErbB3 antibody that has demonstrated efficacy in vivo. It has strategic partnerships with OSI Pharmaceuticals, Inc., Merck, and Biogen Idec, Inc. AVEO Pharmaceuticals was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. The company was founded in 2001 and is based in Cambridge, Massachusetts.

Advisors' Opinion:

• [By Chris Rees]

  We have previously published two articles about Aveo Pharmaceuticals (AVEO) and its kidney cancer drug Tivozanib. This article will make more sense if you read those articles first. You can find the first one here and the second one here. We have been working on the Aveo story for over a year, and were convinced the FDA would interpret the data results the same way we did and draw the same conclusions. But it did not. We have no problem admitting we were shocked and stunned at the result -- we still are.

• [By Sean Williams]

  What: Shares of AVEO Pharmaceuticals (NASDAQ: AVEO  ) , a cancer therapeutics company, collapsed as much as 27% following the release of briefing documents today in anticipation of AVEO's meeting with the Food and Drug Administration panel on Thursday.

Hot Life Sciences Companies For 2014: Actavis Inc (ACT)

Actavis, Inc., formerly Watson Pharmaceuticals, Inc., incorporated on February 1, 1985, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company also develops and out-licenses generic pharmaceutical products primarily in Europe through its Medis third-party business. The Company operates in three segments: Actavis Pharma, Actavis Specialty Brands and Anda Distribution. On January 23, 2013, the Company completed the acquisition of Uteron Pharma SA. On October 29, 2012, the Company sold its Rugby OTC pharmaceutical products and trademarks to The Harvard Drug Group, L.L.C. On January 24, 2012, the Company completed the acquisition of Ascent Pharmahealth Ltd.

Actavis Pharma Segment

Actavis Pharma Segment is engaged in the development, manufacturing and sale of generic, branded generic and OTC pharmaceutical products. The Company�� portfolio of generic products includes products it has developed internally and products licensed from and distributed for third parties. The Company sells its generic prescription products primarily under the Watson Laboratories, Watson Pharma and Actavis Pharma labels, and its over-the-counter generic products under private label.

Actavis Specialty Brands Segment

The Company markets a number of branded products to physicians, hospitals, and other markets that it serves. The Company classifies these trademarked products as its brand pharmaceutical products. In April 2012, it launched Gelnique 3% (oxybutynin), a clear, odorless topical gel. Gelnique 3% was obtained through an exclusive licensing agreement with Antares. The Company�� promoted products are Rapaflo, Gelnique, Trelstar, Androderm, Generess Fe and Crinone. The Company�� Actavis Specialty Brands segment also receives other revenues consisting of co-promotion revenue and royaltie! s.

Anda Distribution Segment

The Company Anda Distribution business primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables and over-the-counter medicines to independent pharmacies, alternate care providers (hospitals, nursing homes and mail order pharmacies), pharmacy chains and physicians��offices. In addition, it sells to members of buying groups, which are independent pharmacies that join together to enhance their buying power. As of December 31, 2012, the Company distributes products from its facilities in Weston, Florida, Groveport, Ohio, and Olive Branch, Mississippi, as well as a small volume of product from Puerto Rico.

The Company competes with Teva Pharmaceutical Industries, Ltd., Mylan Inc., Sandoz, Inc, McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc.,

Advisors' Opinion:

• [By Victor Selva]

  Lastly, Actavis PLC (ACT) occupied the third place in Apex's portfolio by the end of the quarter. The firm is a $32 billion market cap specialty pharmaceutical company. This stock was added to the fund麓s portfolio in the last quarter, and is Apex's largest new buy of the period. Its shares are currently valued at $52.1 million.

• [By Dimitra DeFotis]

  Here are insights on the conference call that ensued, from�ISI’s biotech and pharmaceutical industry analyst�Mark Schoenbaum,�paraphrased:

  Merck wants “bolt-ons” acquisitions (like Idenix Pharmaceuticals (IDIX)) versus big purchases. Moreover, it is not interested in a deal primarily or solely for tax inversion purposes … �[That's not ruling out the possibility of buying a foreign company to avoid U.S. taxes, but the language seems contrary to the foreign-merger possibilities for other healthcare companies, including�Valeant Pharmaceuticals (VRX), Actavis (ACT), Pfizer (PFE), AbbVie (ABBV), Medtronic (MDT) and even�Walgreen (WAG).] Merck sees a “high likelihood” of success for the four-week Hepatitis C regimen from C-SWIFT when presented at a medical conference this fall. (The combo treatment includes Gilead’s Sovaldi, already on the market, and a Merck regimen.) The company sees “lots of opportunities” to possibly accelerate Food & Drug Administration filings for an experimental immuno-oncology drug for lung cancer patients. It’s excited about the expected Aug. 14 FDA decision on insomnia drug Suvorexant. (Wall Street is bearish on commercial prospects.) Merck expects U.S. volume growth for diabetes drug Januvia (which is roughly 25% of earnings) in the second half of 2014.

  For healthcare investing ideas and insight on so-called tax inversions, see the Barrons.com Q&A with Andy Acker, manager of the Janus Global Life Sciences Fund (JAGLX): “Undervalued Biotech Stocks Help Fund Beat the Index,” July 29. (Subscription required) One insight from Acker:

• [By Jake L'Ecuyer]

  Equities Trading UP
  Forest Laboratories (NYSE: FRX) shot up 30.07 percent to $92.86 after Actavis (NYSE: ACT) announced its plans to buy Forest Labs for $25 billion. Analysts at Morgan Stanley upgraded Forest Labs from Equal-Weight to Overweight.

• [By Ben Levisohn]

  Price target to $100 now – our ongoing positive thesis is: 1) upcoming Crohn’s data will increase Street confidence in $1B opportunity, 2) eventual settlement with Actavis�(ACT) in 2015, 3) second inning of pipeline thesis, 4) company keeps buying back more stock, 5) will bullish new 2020 long-term guidance start becoming a topic of conversation?

Hot Life Sciences Companies For 2014: Callon Petroleum Co (CPE)

Callon Petroleum Company (Callon), incorporated on March 29, 1994, is an independent oil and natural gas company. It is focused on growing production and reserves from its oil-weighted multi-play assets in the Permian Basin. In 2013, the Company shifted its operations from the offshore waters in the Gulf of Mexico to the onshore, Permian Basin region in Texas.

The Company operates 100% of its Permian acreage. As of December 31, 2013, the Company�� proved reserves were 14.9 million barrels of oil equivalent (80% oil and 50% proved developed).

Advisors' Opinion:

• [By Garrett Cook]

  In trading on Friday, energy shares were relative laggards, down on the day by about 0.40 percent. Top losers in the sector included Callon Petroleum Company (NYSE: CPE), down 5.67 percent, and Tesco (NASDAQ: TESO), off 3.99 percent.